PFE · News · 20260923N

Revenue Performance and Mix

PFIZER INC · 2026-09-23 · Importance 30 · Surprise 40

Pfizer’s revenue has been flat as sales of its COVID-19 products continue to decline. Newer and recently acquired medicines increased 18% year over year, led in part by products obtained through the Seagen acquisition. Padcev was identified as a key growth product helping offset weakness in COVID-related and other declining segments. Pfizer’s ability to meet its long-term revenue targets depends on continued growth from these newer products and upcoming pipeline launches.

Key facts

• A smaller segment of Pfizer's newer and recently acquired medicines is showing growth of 18% year-over-year. source
• Pfizer is generating positive free cash flow. source
• Pfizer's revenue has been flat due to shrinking COVID product sales. source
• Pfizer is one of the stocks yielding more than 6%. source